19 October 2022 - NICE has published evidence-based recommendations on the use of zanubrutinib for the treatment of adults with Waldenström’s macroglobulinaemia.

Zanubrutinib is recommended as an option for the treatment of adults with Waldenström's macroglobulinaemia who have had at least one treatment, only if:

• The use of bendamustine hydrochloride and rituximab is also suitable
• BeiGene provides it according to the commercial arrangement

Read NICE technology appraisal guidance